Categories AlphaGraphs, Earnings, Health Care

Key highlights from Moderna’s (MRNA) Q1 2023 earnings results

Moderna, Inc. (NASDAQ: MRNA) reported first quarter 2023 earnings results today.

Total revenue was $1.9 billion, compared to $6.1 billion in the same period a year ago, mainly due to a drop in sales of the company’s COVID-19 vaccines.

Product sales were $1.8 billion, down 69% compared to the prior-year period, driven mainly by lower sales volume.

Net income was $79 million, or $0.19 per share, compared to $3.7 billion, or $8.58 per share, last year.  

The company expects total product sales in the first half of 2023 to be approx. $2 billion. For the second quarter of 2023, sales are expected to be $0.2-0.3 billion.

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top